Libor Havel
Impact in
- Oncology top 2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 38
- Lung Cancer Research Studies 22
- Cancer Immunotherapy and Biomarkers 9
- Colorectal Cancer Treatments and Studies 5
- Pancreatic and Hepatic Oncology Research 4
-
- Lung Cancer Treatments and Mutations 28
- Lung Cancer Diagnosis and Treatment 8
- Co-authors
- Luboš Petruželka (8 shared papers)Petr Zatloukal (8 shared papers)Milada Zemanová (9 shared papers)A Kubík (3 shared papers)E Kr̆epela (2 shared papers)Ladislav Pecen (3 shared papers)Libor Judas (2 shared papers)Pavel Fiala (1 shared paper)
- Journals
- Annals of Oncology (13 papers)Journal of Clinical Oncology (12 papers)Lung Cancer (8 papers)Journal of Thoracic Oncology (5 papers)ESMO Open (2 papers)
- Partner nations
- CzechiaUnited StatesGermany
In The Last Decade
Libor Havel
48 papers receiving 1.7k citations
Libor Havel's Hit Papers
Peers
Comparison fields: 5 of 64
- Oncology 1.0k
- Pulmonary and Respiratory Medicine 775
- Epidemiology 253
- Otorhinolaryngology 26
- Immunology 111
Countries citing papers authored by Libor Havel
This map shows the geographic impact of Libor Havel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libor Havel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libor Havel more than expected).
Fields of papers citing papers by Libor Havel
This network shows the impact of papers produced by Libor Havel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libor Havel. The network helps show where Libor Havel may publish in the future.
Co-authors
The 25 scholars most cited alongside Libor Havel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 410 |
| 2 | 2004 | 347 | |
| 3 | 2003 | 141 | |
| 4 | 2023 | 69 | |
| 5 | 2004 | 52 | |
| 6 | 2022 | 50 | |
| 7 | 2013 | 45 | |
| 8 | Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial | 2003 | 41 |
| 9 | 2019 | 39 | |
| 10 | 2014 | 38 | |
| 11 | 2019 | 37 | |
| 12 | 2020 | 34 | |
| 13 | 2020 | 34 | |
| 14 | 2013 | 30 | |
| 15 | 2016 | 30 | |
| 16 | 2023 | 28 | |
| 17 | 2022 | 28 | |
| 18 | 2001 | 28 | |
| 19 | 2024 | 27 | |
| 20 | 2003 | 26 |
About Libor Havel
Libor Havel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Epidemiology and Surgery, having authored 54 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Research Studies (22 papers), Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Diagnosis and Treatment (8 papers), Cancer therapeutics and mechanisms (8 papers), Colorectal Cancer Treatments and Studies (5 papers), Neuroendocrine Tumor Research Advances (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). The work is most often cited by research in Oncology (1.0k citations), Pulmonary and Respiratory Medicine (775 citations), Epidemiology (253 citations), Otorhinolaryngology (26 citations) and Immunology (111 citations). Libor Havel has collaborated with scholars based in Czechia, United States and Germany. Frequent co-authors include Luboš Petruželka, Petr Zatloukal, Milada Zemanová, A Kubík, E Kr̆epela, Ladislav Pecen, Libor Judas, Pavel Fiala, Filip Jankú and Yi‐Long Wu. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Lung Cancer, Journal of Thoracic Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.